Black Diamond Therapeutics, Inc.
BDTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $51 | $59 | $64 | $97 |
| G&A Expenses | $27 | $27 | $28 | $30 |
| SG&A Expenses | $27 | $27 | $28 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $79 | $86 | $93 | $127 |
| Operating Income | -$79 | -$86 | -$93 | -$127 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $9 | $4 | $2 | $1 |
| Pre-Tax Income | -$70 | -$82 | -$91 | -$126 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$70 | -$82 | -$91 | -$126 |
| % Margin | – | – | – | – |
| EPS | -1.27 | -1.88 | -2.52 | -3.47 |
| % Growth | 32.4% | 25.4% | 27.4% | – |
| EPS Diluted | -1.27 | -1.88 | -2.52 | -3.47 |
| Weighted Avg Shares Out | 55 | 44 | 36 | 36 |
| Weighted Avg Shares Out Dil | 55 | 44 | 36 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$78 | -$86 | -$92 | -$127 |
| % Margin | – | – | – | – |